{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:35:22Z","timestamp":1793900122416,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jinf.2021.12.033","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T09:24:43Z","timestamp":1640424283000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged \u226550 years: A randomized trial"],"prefix":"10.1016","volume":"84","author":[{"given":"Ji-Young","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Mwakingwe-Omari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeter Yenwo","family":"Molo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginette","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Danier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2021.12.033_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2021.12.033_bib0002","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jinf.2021.12.033_bib0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.12.033_bib0004","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jinf.2021.12.033_bib0005","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0006","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.12.033_bib0007","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.12.033_bib0008","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2021.12.033_bib0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2021.12.033_bib0010","unstructured":"Shingrix prescribing information. Available at https:\/\/www.fda.gov\/media\/108597\/download. Accessed on 28 Jul 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0011","unstructured":"Shingrix summary of product charactersitics. Available at https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf. Accessed on 16 Jun 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0012","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/ahe.09.74","article-title":"Community-acquired pneumonia in elderly patients","volume":"5","author":"Stupka","year":"2009","journal-title":"Aging Health"},{"key":"10.1016\/j.jinf.2021.12.033_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"van Aalst","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0014","unstructured":"CDC. Adult Immunization Schedule by Vaccine and Age Group. Available at https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html. Accessed on 11 Jul 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0015","unstructured":"ACIP. Considerations for Age-Based and Risk-Based Use of PCV15 and PCV20 among U.S. Adults and Proposed Policy Options Available at https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/02-Pneumococcal-Kobayashi-508.pdf. Accessed on 11 Nov 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0016","unstructured":"ECDC. Pneumococcal disease: recommended vaccinations. Available at https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1. Accessed on 2 Dec 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0017","unstructured":"NHS. Pneumococcal vaccine overview. Available at https:\/\/www.nhs.uk\/conditions\/vaccinations\/pneumococcal-vaccination\/. Accessed on 2 Dec 2021.:"},{"key":"10.1016\/j.jinf.2021.12.033_bib0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000504486","article-title":"Strategies to improve vaccine uptake throughout adulthood","volume":"43","author":"Ecarnot","year":"2020","journal-title":"Interdiscip Top Gerontol Geriatr"},{"key":"10.1016\/j.jinf.2021.12.033_bib0019","unstructured":"ACIP. General best practice guidelines for immunization. Available at https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf. Accessed on 11 Nov 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0020","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0021","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: a randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.12.033_bib0022","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550\u00a0years of age: a randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.12.033_bib0023","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jinf.2021.12.033_bib0024","unstructured":"Prevnar 13 Prescribing Information. Available at https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-Prevnar-13.pdf. Accessed on 07 Apr 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0025","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0026","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1016\/j.vaccine.2004.03.049","article-title":"Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine","volume":"22","author":"Bogaert","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.12.033_bib0027","unstructured":"C.D.C. Vaccine Recommendations and Guidelines of the ACIP. Available at https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html#simultaneous. Accessed on 2 Dec 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0028","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2021.12.033_bib0029","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0030","unstructured":"Prevenar 13 summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prevenar-13-epar-product-information_en.pdf. Accessed on 07 Apr 2021."},{"key":"10.1016\/j.jinf.2021.12.033_bib0031","doi-asserted-by":"crossref","first-page":"404","DOI":"10.14336\/AD.2018.0512","article-title":"Efficacy and safety of the pneumococcal conjugate-13 valent vaccine in adults","volume":"10","author":"Marra","year":"2019","journal-title":"Aging Dis"},{"key":"10.1016\/j.jinf.2021.12.033_bib0032","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40264-021-01076-w","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials","volume":"44","author":"L\u00f3pez-Fauqued","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.jinf.2021.12.033_bib0033","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1016\/j.vaccine.2019.09.028","article-title":"Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials","volume":"37","author":"Willer","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.12.033_bib0034","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials","volume":"37","author":"L\u00f3pez-Fauqued","year":"2019","journal-title":"Vaccine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321006514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321006514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:33:41Z","timestamp":1759008821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445321006514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0163445321006514"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2021.12.033","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged \u226550 years: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2021.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}